Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Size, Share & Trend Analysis 2029
- Product Id: AIMR 1209
- Pages: 200
- Publish Date: Apr-2023
- Category: Life Sciences
Fill Details
Verify Email
Check your inbox for Sample + Methodology
Note: For delivery of sample pages you must have a Domain Specific EmailID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc are not accepted
Segments
By Type
- PD-1 Inhibitors
- PD-L1 Inhibitors
By Application
- Hodgkin Lymphoma
- Kidney Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Others
Regions and Country
North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Sweden
- Netherlands
- Turkey
- Switzerland
- Belgium
- Rest of Europe
Asia-Pacific
- South Korea
- Japan
- China
- India
- Australia
- Philippines
- Singapore
- Malaysia
- Thailand
- Indonesia
- Rest of APAC
Latin America
- Mexico
- Colombia
- Brazil
- Argentina
- Peru
- Rest of South America
Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of MEA
Key Players
- Bristol-Myers Squibb
- AstraZeneca
- Merck
- Roche
- Regeneron Pharmaceuticals
- Bristol-Myers Squibb
- Janssen Research and Development
- 4D pharma
- 4SC AG
- OncoSec Medical
- Mirati Therapeutics
- Ascentage Pharma Group
- ENB Therapeutics
- Exicure
- Eisai
- Kartos Therapeutics
- Exelixis
- ImmunityBio
+44-1173181773
sales@brandessenceresearch.com
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com
JOIN USFIND ASSISTANCE
LONDON OFFICE
AI® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
FOLLOW US
© Copyright 2024-25 AI® Market Research and Consulting. All Rights Reserved | Designed by AI® Market
